


2017 MID-ATLANTIC
CONFERENCE

7th ANNUAL CURRENT CONCEPTS IN
VASCULAR THERAPIES

2017


Rafael Malgor, MD
Assistant Professor
of Surgery
The University of
Oklahoma, Tulsa

**Endovascular Is The Way To Go:
Revascularize As Many Vessels As
You Can**



Background

- Lower extremity anatomy (below the inguinal ligament)
 - Anatomy and disease
 - Multiple collateral pathways
 - 3 vessels to the foot
 - Multilevel disease



How can limb revascularization (salvage) be achieved?

- Different approaches
 1. Treating as many vessels as can be recanalized using catheter-based technology (**THE WAY TO GO!**)
 2. Treating not all but at least two main below-the-knee vessels
 3. Attempting to provide flow to some collaterals in order to maximize foot perfusion (rare situations)
 4. Bypassing an obstruction by using vein or prosthesis conduit




Endovascular Era

- Endovascular treatment has evolved over the past 50 years...from rigid to flexible/comformable catheters and stents



Charles Dotter, M.D.
Leg angioplasty
concept, 1964




Endovascular Modalities

- Balloon angioplasty
 - Regular, not coated
 - Cryo-balloon (“cold” angioplasty)
 - Cutting or scoring balloon
 - Drug coated → Paclitaxel* (anti-rejection med)
- Stenting
 - Bare metal
 - Drug eluted → Sirolimus, Paclitaxel*, and Everolimus
- Atherectomy
 - Laser, rotational, orbital, directional




Balloon Angioplasty

- Arterial stenosis dilated by balloon inflation
- Atherosclerotic plaque remodeling
- Can be repeated if recurrence
- Often, no foreign body left behind
- Can be combined with stents





Balloon Angioplasty



Regular balloon




Drug coated balloon




Inner balloon: Contains the gas and pressure
Middle layer: Insulates and has RO markers
Outer balloon: Pebax® balloon expands passively

Cryo-balloon



Cutting and scoring balloon




Balloon Angioplasty

77 year-old diabetic female on chronic hemodialysis
with left forefoot chronic nonhealing ulcer



Stenting


- Scaffold providing support
- Less recoiling
- Can be bare metal or covered
- Can be drug eluted
- No clear superiority compared to balloon angioplasty
- Important when antegrade dissections occur (against the flow)




Stents



Bare metal stents



Drug-eluting stents






Covered stents




Stenting - Case

- 55yo poorly controlled diabetic, smoker female




Atherectomy


- Reduce plaque burden by shaving, drilling or pulverizing it
- Several devices in the market




Atherectomy




Laser atherectomy



Rotational
atherectomy






Directional
atherectomy



Atherectomy case

- 74 year-old male smoker with pain at rest



Endovascular Era

- Several endovascular devices to treat lower extremity arterial disease in a minimally invasive way!

Endovascular	Bypass
A puncture	At least two incisions
Same-day procedure	A few nights in the hospital
Local anesthesia/sedation	General or regional anesthesia
Flexible scheduling (“cath lab”)	Operating room availability
One procedure can tackle several arteries – less hassle, more flow to the foot!	One target vessel that can signify one vessel to the foot




Literature Review

- Claudicants

Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication

Society for Vascular Surgery Lower Extremity Guidelines Writing Group: Michael S. Conte, MD, (Co-Chair),^a Frank B. Pomposelli, MD, (Co-Chair),^b Daniel G. Clair, MD,^c Patrick J. Geraghty, MD,^d James F. McKinsey, MD,^e Joseph L. Mills, MD,^f Gregory L. Moneta, MD,^g M. Hassan Murad, MD,^h Richard J. Powell, MD,ⁱ Amy B. Reed, MD,^j Andres Schanzer, MD,^k and Anton N. Sidawy, MD, MPH,^l San Francisco, Calif; Boston and Worcester, Mass; Cleveland, Ohio; St. Louis, Mo; New York, NY; Tucson, Ariz; Portland, Ore; Rochester, Minn; Lebanon, NH; Hershey, Pa; and Washington, D.C.

J Vasc Surg. 2015 Mar;61(3 Suppl):2S-41S.



Literature Review

- Claudicants (aortoiliac disease)

Clinical question	Data source	Finding	Quality of evidence
The effect of endovascular vs open surgery for AIOD on the outcomes of mortality, complications, and patency	Meta-analyses of mostly <u>nonrandomized series</u> (AIOD, not all IC) ¹³⁹	The open bypass group experienced more complications and greater 30-day mortality. At 1, 3, and 5 years, primary patency rates were greater in the open bypass group	B-C
The effect of PTA vs stent placement for AIOD on the outcomes of mortality, complications, and patency	Meta-analyses of mostly <u>nonrandomized series</u> (AIOD, data provided for IC). ¹³⁷ Meta-analyses of mostly <u>nonrandomized series</u> (class C and D aortoiliac lesions) ¹³⁸	Complication and mortality rates were similar. Immediate technical success rate (PTA group, 91%; stent group, 96%); 4-year primary patency rates for PTA (65% for stenosis, 54% for occlusions) and for stents (77% for stenoses, 61% for occlusions)	B-C
The effect of endovascular vs open surgery for extensive AIOD on the outcomes of mortality, complications, and patency	Meta-analyses of <u>nonrandomized series</u> of EVT for extensive AIOD ¹⁸⁸	With endovascular approach, mortality ranged 1.2%-6.7% and complications ranged 3%-45%. Clinical symptoms improved in 83% to 100%. Technical success was achieved in 86% to 100% of the patients. The 4-year or 5-year primary and secondary patency rates were 60% to 86% and 80% to 98%, respectively	B-C



Literature Review

- Claudicants (femoropopliteal disease)

Clinical question	Data source	Funding	Quality of evidence
Endovascular vs surgical reconstruction	Four RCTs and six observational studies reporting on 2817 patients with FP arterial disease ²³³	EVT was associated with lower 30-day morbidity (OR, 2.93; 95% CI, 1.34-6.41) and higher technical failure (OR, 0.10; 95% CI, 0.05-0.22) than bypass surgery. No difference in 30-day mortality (OR, 0.92; 95% CI, 0.55-1.51). Higher primary patency in the surgical treatment arm was found at 1 (OR, 2.42; 95% CI, 1.37-4.28), 2 (OR, 2.03; 95% CI, 1.20-3.45), and 3 (OR, 1.48; 95% CI, 1.12-1.97) years after intervention. Progression to amputation occurred more commonly in the endovascular group at the end of the second (OR, 0.60; 95% CI, 0.42-0.86) and third (OR, 0.55; 95% CI, 0.39-0.77) year of intervention. The bypass group had higher amputation-free (OR, 1.31; 95% CI, 1.07-1.61) and overall survival (OR, 1.29; 95% CI, 1.04-1.61) rates at 4 years	C (risk of bias, indirectness because most trials enrolled CLI patients)



Literature Review

- Claudicants (femoropopliteal disease)

The effect of stenting vs no stenting in patients with IC on morbidity, mortality and patency

Balloon angioplasty with optional stenting vs routine stenting with nitinol stents

Comparison of various stents

Meta-analysis of 8 RCTs (968 patients with IC or CLI and SFA disease)¹⁸⁹

Meta-analysis of 4 RCTs (627 patients with IC or CLI and SFA disease)²³⁴

Network meta-analysis of 16 RCTs (2532 patients with IC or CLI and FP arterial disease)²³⁵

Primary patency better with stenting at 6 months but not 12 months


Mortality was similar in both groups (OR, 0.83; 95% CI, 0.39-1.77). Technical success was significantly higher in the stenting group (96% vs 64%; OR, 0.31; 95% CI, 0.09-0.92). The 12-month binary restenosis rate was significantly lower in the primary stenting group (OR, 3.02; 95% CI, 1.3-6.71)⁷

Technical success was highest with covered stents. Vascular restenosis was lowest with paclitaxel DES and with paclitaxel-coated balloons. Major amputations were rare in all treatment and control groups (pooled amputation rate of 0.7 events/100 person-years)

C (indirectness due to CLI patients included and imprecision of long-term outcome)

C (indirectness due to CLI patients included and imprecision)


C (indirect comparisons, CLI patients included, imprecision)



Literature Review - CLI

- BASIL trial (Bypass versus Angioplasty in Severe Ischemia of the Leg)
 - Sponsored by the United Kingdom National Institute of Health Research Technology Assessment Program
 - Started in 1996, the trial enrolled 452 patients over a 5-year period
 - There was no difference in amputation-free survival between both the arms (57% for Bypass and 52% for percutaneous transluminal angioplasty at 3 years)
 - Questionable endovascular strategy (excluded stenting) and surveillance methods (no hemodynamic studies)

(J Vasc Surg. 2010 May;51(5 Suppl):5S-17)



Literature Review - CLI

- BEST-CLI (Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia)
 - Ongoing trial funded by the National Lung Heart and Blood Institute of the National Institutes of Health
 - Randomization of patients with either pain at rest or tissue loss (ulcers, wounds) into endo or open
 - No restriction regarding endovascular modality
 - Aim: to enroll 2100 patients at 120 sites in North America over the course of 4 years (~900 patients)




Where is the evidence?

- Currently, there is no strong data showing superiority of one type of endovascular method over the others despite recent “network” meta-analysis (J Vasc Surg. 2017 Jan;65(1):234-245)
- Several trials sponsored by companies involved in developing new technology
- Lack of high-quality publications (with no conflict of interest) comparing surgery versus endovascular treatment (BEST-CLI under way)




The Angiosome concept

- Derived from plastics and cardiac surgery
- 40 angiosomes in the body → 6 of them in the foot!
- Acute versus chronic presentation
- Muscle ischemia conditioning




The Angiosome concept

- Peripheral vascular issues with the theory
 - Interangiosome connections for perfusion
 - Perfusion is a matter of flow/pressure to the target area
 - “Choke vessels”: reduced-caliber anastomosing vessels. Normally the barrier in the vasculature



Case Presentation

- 60yo M (non smoker)
 - Type II diabetes
 - 3-month hx of second toe non-healing wound
 - Treated unsuccessfully with wound care + hyperbaric oxygen therapy



What is the best option out there for limb salvage?

- Patient selection is key...not everyone is a candidate (very long segment occlusions)
- Start minimally invasive...less is more.
- Open as many vessels as possible to give the leg the best chance to heal...go big or go home!



Endovascular is the way to go!



Thank you

